{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-209437","form_type":"8-K","ticker":"CYTK","cik":"0001061983","company_name":"CYTOKINETICS INC","filed_at":"2025-09-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.229708+00:00","generated_at":"2026-05-17T05:56:30.942799+00:00","sec_items":["1.01","2.03","3.02","8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cytokinetics issues $750M 1.75% convertible notes; refinances $399.5M of 2027 notes","bullets":["Issued $750M aggregate principal of 1.75% convertible senior notes due 2031; net proceeds ~$729.4M.","Used ~$402.5M cash and 2,168,806 common shares to exchange $399.5M of existing 3.50% notes due 2027.","Initial conversion price ~$68.42 per share, ~37.5% premium over $49.76 last sale price.","Remaining proceeds to fund aficamten commercial launch, development, pipeline, and general corporate purposes.","Notes not redeemable before Oct 6, 2028; convertible under certain stock price and event conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-209437","json":"https://secwatch.observer/filing/0001193125-25-209437.json","markdown":"https://secwatch.observer/filing/0001193125-25-209437.md","text":"https://secwatch.observer/filing/0001193125-25-209437.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1061983/000119312525209437/0001193125-25-209437-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1061983/000119312525209437/d933506d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:56:30.942799+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c7e8634a8101251c9b2108d05403ac6d43207daf","claim":"CYTOKINETICS INC incurred convertible notes of $750.0 million aggregate principal amount with initial purchasers at 1.75% per year maturing October 1, 2031.","evidence_excerpt":"On September 19, 2025, Cytokinetics, Incorporated (the “Company”) issued $750.0 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2031 (the “Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $100.0 million aggregate principal amount of Notes.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000119312525209437/0001193125-25-209437-index.htm","confidence":0.98}],"comparable_filings":[{"accession":"0001492691-26-000042","ticker":"KNX","company_name":"Knight-Swift Transportation Holdings Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Knight-Swift closes $1.5B convertible note offering at 1.00% due 2031; proceeds used to repay term loans and revolver","event_type":"debt","sec_items":["1.01","2.03","3.02","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: debt_financing","same SEC item: 1.01, 2.03, 3.02, 8.01, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001492691-26-000042","json":"https://secwatch.observer/filing/0001492691-26-000042.json","markdown":"https://secwatch.observer/filing/0001492691-26-000042.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1492691/000149269126000042/0001492691-26-000042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1492691/000149269126000042/knx-20260505.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On September 19, 2025, Cytokinetics, Incorporated (the “Company”) issued $750.0 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2031 (the “Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $100.0 million aggregate principal amount of Notes.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000119312525209437/0001193125-25-209437-index.htm","comparable_excerpt":"On May 8, 2026, Knight-Swift Transportation Holdings Inc. (the \"Company\") completed its previously announced private offering (the \"Offering\") of $1.5 billion aggregate principal amount of 1.00% Convertible Senior Notes due 2031","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1492691/000149269126000042/0001492691-26-000042-index.htm"}},{"accession":"0001104659-26-057128","ticker":"PUMP","company_name":"ProPetro Holding Corp.","filed_at":"2026-05-07T23:59:59+00:00","headline":"ProPetro issues $690M zero-coupon convertible notes due 2031, expands credit facility","event_type":"debt","sec_items":["1.01","2.03","3.02","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: debt_financing","same SEC item: 1.01, 2.03, 3.02, 8.01, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057128","json":"https://secwatch.observer/filing/0001104659-26-057128.json","markdown":"https://secwatch.observer/filing/0001104659-26-057128.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680247/000110465926057128/0001104659-26-057128-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680247/000110465926057128/tm2613899d1_8k.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On September 19, 2025, Cytokinetics, Incorporated (the “Company”) issued $750.0 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2031 (the “Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $100.0 million aggregate principal amount of Notes.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000119312525209437/0001193125-25-209437-index.htm","comparable_excerpt":"On May 7, 2026, ProPetro Holding Corp. (the “ Company ”), issued $690 million aggregate principal amount of its 0.00% Convertible Senior Notes due 2031","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1680247/000110465926057128/0001104659-26-057128-index.htm"}},{"accession":"0001213900-26-051931","ticker":"RENX","company_name":"RenX Enterprises Corp.","filed_at":"2026-05-05T23:59:59+00:00","headline":"RenX Enterprises raises up to $100M via tranched convertible note and warrant private placement","event_type":"debt","sec_items":["1.01","2.03","3.02","7.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: debt_financing","same SEC item: 1.01, 2.03, 3.02, 8.01, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-051931","json":"https://secwatch.observer/filing/0001213900-26-051931.json","markdown":"https://secwatch.observer/filing/0001213900-26-051931.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1959023/000121390026051931/0001213900-26-051931-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1959023/000121390026051931/ea0288854-8k_renx.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On September 19, 2025, Cytokinetics, Incorporated (the “Company”) issued $750.0 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2031 (the “Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $100.0 million aggregate principal amount of Notes.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000119312525209437/0001193125-25-209437-index.htm","comparable_excerpt":"Purchase Agreement,\nthe Company (i) issued and sold to the Purchasers, at the initial closing on May 4, 2026 (the “Initial Closing”), Notes in\nthe aggregate principal amount of $6,300,000 (the “Initial Notes”) and warrants (the “Initial Warrants”) to purchase\nan aggregate of 3,917,099 shares of Common Stock (which is equal to 180% of the face value of the Initial","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1959023/000121390026051931/0001213900-26-051931-index.htm"}},{"accession":"0001213900-26-050957","ticker":"BRLS","company_name":"Borealis Foods Inc.","filed_at":"2026-05-01T23:59:59+00:00","headline":"Borealis Foods enters $17M term loan with Oxus, repays Frontwell; potential equity conversion up to $33.3M","event_type":"debt","sec_items":["1.01","1.02","2.03","3.02","5.02","8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: debt_financing","same SEC item: 1.01, 2.03, 3.02, 8.01, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-050957","json":"https://secwatch.observer/filing/0001213900-26-050957.json","markdown":"https://secwatch.observer/filing/0001213900-26-050957.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1852973/000121390026050957/0001213900-26-050957-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1852973/000121390026050957/ea0288749-8k_borealis.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On September 19, 2025, Cytokinetics, Incorporated (the “Company”) issued $750.0 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2031 (the “Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $100.0 million aggregate principal amount of Notes.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000119312525209437/0001193125-25-209437-index.htm","comparable_excerpt":"SPAC sponsor and a significant shareholder of\nthe Company. Pursuant to the Credit Agreement, Oxus provided\na term loan to the Borrowers in an aggregate principal amount of up to $17.0 million (the “Term Loan”). The obligations under\nthe Credit Agreement are guaranteed by the Company, Borealis IP Inc., and Palmetto Gourmet Foods (Canada) Inc. (collectively, the","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1852973/000121390026050957/0001213900-26-050957-index.htm"}},{"accession":"0001213900-26-054183","ticker":"EMAT","company_name":"Evolution Metals & Technologies Corp.","filed_at":"2026-05-11T23:59:59+00:00","headline":"EMAT secures $100M convertible debenture facility from Yorkville; first $20M tranche issued","event_type":"debt","sec_items":["1.01","2.03","3.02","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: debt_financing","same SEC item: 1.01, 2.03, 3.02, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-054183","json":"https://secwatch.observer/filing/0001213900-26-054183.json","markdown":"https://secwatch.observer/filing/0001213900-26-054183.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1866226/000121390026054183/0001213900-26-054183-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1866226/000121390026054183/ea0290073-8k_evolution.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On September 19, 2025, Cytokinetics, Incorporated (the “Company”) issued $750.0 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2031 (the “Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $100.0 million aggregate principal amount of Notes.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000119312525209437/0001193125-25-209437-index.htm","comparable_excerpt":"The first Convertible Debenture (the “First Debenture”) in the principal amount of $20,000,000 was issued on May 7, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1866226/000121390026054183/0001213900-26-054183-index.htm"}},{"accession":"0001213900-26-053894","ticker":"TBH","company_name":"Brag House Holdings, Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Brag House issues $2.5M convertible notes at 25% OID; proceeds for House of Doge merger","event_type":"debt","sec_items":["1.01","2.03","3.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: debt_financing","same SEC item: 1.01, 2.03, 3.02, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-053894","json":"https://secwatch.observer/filing/0001213900-26-053894.json","markdown":"https://secwatch.observer/filing/0001213900-26-053894.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1903595/000121390026053894/0001213900-26-053894-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1903595/000121390026053894/ea0289773-8k_braghouse.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On September 19, 2025, Cytokinetics, Incorporated (the “Company”) issued $750.0 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2031 (the “Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $100.0 million aggregate principal amount of Notes.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000119312525209437/0001193125-25-209437-index.htm","comparable_excerpt":"The issuance of the Notes in the aggregate original principal amount of $2,500,000 constitutes the creation of a direct financial obligation of the Company. The Notes bear interest at 12.0% per annum, mature on February 4, 2027","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1903595/000121390026053894/0001213900-26-053894-index.htm"}},{"accession":"0001104659-26-057138","ticker":"OCGN","company_name":"Ocugen, Inc.","filed_at":"2026-05-07T23:59:59+00:00","headline":"Ocugen completes $115M convertible note offering at 6.75%, repays Avenue loan","event_type":"debt","sec_items":["1.01","1.02","2.02","2.03","3.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: debt_financing","same SEC item: 1.01, 2.03, 3.02, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057138","json":"https://secwatch.observer/filing/0001104659-26-057138.json","markdown":"https://secwatch.observer/filing/0001104659-26-057138.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926057138/0001104659-26-057138-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926057138/tm2613898d1_8k.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On September 19, 2025, Cytokinetics, Incorporated (the “Company”) issued $750.0 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2031 (the “Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $100.0 million aggregate principal amount of Notes.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000119312525209437/0001193125-25-209437-index.htm","comparable_excerpt":"On May 7, 2026, Ocugen, Inc. (the “Company”) completed its previously announced private offering (the “offering”) of $115.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the “notes”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926057138/0001104659-26-057138-index.htm"}},{"accession":"0001360604-26-000047","ticker":"HR","company_name":"Healthcare Realty Trust Inc","filed_at":"2026-05-07T23:59:59+00:00","headline":"HR subsidiary issues $700M 3.00% exchangeable senior notes due 2032","event_type":"debt","sec_items":["1.01","2.03","3.02","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: debt_financing","same SEC item: 1.01, 2.03, 3.02, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001360604-26-000047","json":"https://secwatch.observer/filing/0001360604-26-000047.json","markdown":"https://secwatch.observer/filing/0001360604-26-000047.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1360604/000136060426000047/0001360604-26-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1360604/000136060426000047/hr-20260507.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On September 19, 2025, Cytokinetics, Incorporated (the “Company”) issued $750.0 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2031 (the “Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $100.0 million aggregate principal amount of Notes.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000119312525209437/0001193125-25-209437-index.htm","comparable_excerpt":"issued $700,000,000 aggregate principal amount of its 3.00% Exchangeable Senior Notes due 2032","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1360604/000136060426000047/0001360604-26-000047-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}